Objective:To study the expression of COX-2, E-cadherin and VEGF in thyroid carcinoma and its clinical significance.Methods:Expression of COX-2, E-cadherin and VEGF was detected in 68 cases with thyroid carcinoma,16 cases with thyroid adenomas and 16 cases of normal thyroid tissues by 2-Step Plus immunohistochemical method and Find the relations between COX-2, E-cadherin,VEGF and thyroid carcinoma s histological stage, TNM stages, pathological type, lymph node metastasis status.Results:1. The expression of COX-2, E-cadherin and VEGF in 68 cases with thyroid carcinoma was 63.2%,66.2% and 61.8% respectively,has significant difference (P<0.05) compared with the expression of these proteins in thyroid adenomas and normal thyroid tissues.2.The expression of COX-2, E-cadherin and VEGF was significantly different with histological stage, TNM stages,pathological type and with lymph node metastasis status (P<0.05)in thyroid carcinoma, but there is no statistical sense difference among thyroid carcinoma patients, gender, age, tumor size, envelope's integrity(P>0.05).3. The expression of E-cadherin was negatively correlated with the expression of VEGF and COX-2 (r=-0.423, r=-0.413, P<0.01). Expression of COX-2 was positively related to the expression of VEGF(r=0.659, P<0.01).4. By Single factor analysis,the expression of COX-2, E-cadherin and VEGF in thyroid cancer, the survival rate differences between negative and positive groups had statistical significance (P<0.05). COX-2 and VEGF positive group were with bad prognosis, E-cadherin negative group was with good prognosis.5. By multivariate analysis,the expression of COX-2, E-cadherin and VEGF,histological stage, TNM stages, pathological type, lymph node metastasis status are the indepent prognosis factors that affecting thyroid carcinoma patients survival rate.Conclusion:COX-2, E-cadherin and VEGF play an important role in carcinogenesis and development of thyroid carcinoma. Combined detection can provide valuable evidence for estimation of aggressive degree and prognosis of thyroid carcinoma.
|